Skip to content

Kidney and liver blood circulation of the treatment of perimenopausal depression transcriptome sequencing

Kidney and liver blood circulation of the treatment of perimenopausal depression transcriptome sequencing

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2024000385
Enrollment
Unknown
Registered
2024-09-05
Start date
2024-07-24
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perimenopausal depression

Interventions

prior treatment:N/A

Sponsors

Guang'anmen Hospital of Chinese Academy of traditional Chinese medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
40 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1: 1) Voluntary participation and signed informed consent; 2: 2) Perimenopausal women aged 45-65 years; 3: 3) meet the diagnostic criteria of depression (Chinese Classification of Mental Disorders and Diagnostic Criteria (Third edition)) and the total score of Hamilton Depression Rating Scale (HAMD) was 8-34; 4: 4) in accordance with the traditional Chinese medicine "all CARDS" before and after menopause kidney liver blood stasis (gynecology of traditional Chinese medicine) diagnostic criteria; 5: 5) proposed to party party for treatment for kidney and liver blood circulation; 6: 6) those who have not taken estrogen drugs or stopped taking estrogen drugs a few months ago; 7: 7) Those who did not take any psychiatric drugs or stopped taking such drugs before 1 month.

Exclusion criteria

Exclusion criteria: 1: 1) merging other serious organic disease or mental illness; 2: 2) there may be a life-threatening disease of heart head blood-vessel. 3: 3) alcohol or drug abuse or dependence in the past 3 months; 4: 4) according to the clinical judgment exists serious suicide risk; 5: 5)patients with total hysterectomy and ovariectomy; 6: 6) having participated in a clinical trial of drug research within one month before enrollment.

Design outcomes

Primary

MeasureTime frame
HAMD;Gene expression levels in PBMC cells;

Countries

China

Contacts

Public ContactXu Fengquan

Guang'anmen Hospital

563862938@qq.com010-88002676

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026